Combined Central and Peripheral Demyelination in a Patient of Multifocal Motor Neuropathy and Positive Anti-myelin Oligodendrocyte Glycoprotein (MOG) Antibodies

Myelin oligodendrocyte glycoprotein (MOG) antibodies have been identified in central nervous system inflammatory demyelinating disorders (MOG antibody disease), inclusive of optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis. The association of MOG antibodies with combined...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-12, Vol.14 (12), p.e32143
Main Authors: Elterefi, Alanood E, Elbashari, Mahfoud Y, Alzaabi, Amani, Abouelnaga, Mohamed E, Eissa, Hesham
Format: Article
Language:English
Subjects:
Allergy/Immunology
Antibodies
Antigens
Aquaporins
Case reports
Coronaviruses
COVID-19
Cytomegalovirus
Dengue fever
Disease
Glycoproteins
Guillain-Barre syndrome
Hepatitis
Internal Medicine
Multiple sclerosis
Nervous system
Neurology
Patients
Peripheral neuropathy
Serology
Spinal cord
Steroids
Velocity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myelin oligodendrocyte glycoprotein (MOG) antibodies have been identified in central nervous system inflammatory demyelinating disorders (MOG antibody disease), inclusive of optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis. The association of MOG antibodies with combined central and peripheral demyelination (CCPD) is not clear. It has been reported in a few cases where MOG antibodies were detected in the serum of patients with chronic inflammatory demyelinating polyneuropathy. However, multifocal motor neuropathy with MOG antibodies is extremely rare. We present a patient who had clinical, neurophysiological, radiological, and biochemical findings that support the diagnosis of CCPD (multifocal motor neuropathy and cord lesion) with MOG antibodies. The patient was treated with a combination therapy of intravenous immunoglobulins plus high-dose methylprednisolone, which resulted in significant improvement.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.32143